Introduction: Current standard treatment for metastatic prostate carcinoma is hormone therapy.The two most commonly used treatments are orchiectomy and gonadotropin releasing hormone (GnRH) analogues, both being equivalent. There is no data regarding the PSA trends in our population. This is the first study that analyzes these issues, and will serve for future studies. Methods: A retrospective cohort study was performed on patients with metastatic prostate cancer (CaPM) who underwent orchiectomy or started treatment with GnRH analogues and were followed over time in order to evaluate the trends of PSA and other associated variables such as, patient age, initial PSA, Gleason score. and TNM. Results: A total of 124 patients were included in the study and divided into two groups; the Orchiectomy (OQ) and the GnRH analogues (BA) group. Monthly PSA records were analyzed and there were no differences in PSA levels over time in these two groups. Progression occurred earlier in the OQ group at 27 months vs 32 months in the BA group. Conclusions: Both treatments are equivalent. Progression occurred earlier in the OQ group. Further studies are needed to measure the specific impact of administrative and insurance issues in the treatment of these patients.
|Translated title of the contribution
|PSA trends in patients with metastatic prostate cancer managed by orquiectomyvs hormone block by gonadotropin releasing hormone analogues
|Number of pages
|Published - 1 Dec 2014